Please login to the form below

Not currently logged in
Email:
Password:

New ABPI head of government affairs

The Association of the British Pharmaceutical Industry(ABPI) has appointed Amanda Stuart as its new head of government affairs

A new head of government affairs has been appointed by the Association of the British Pharmaceutical Industry (ABPI) to spearhead its work with politicians and those in government in both the UK and Europe.

Amanda Stuart, who was formerly associate director at Insight Public Affairs, will play a key role in communicating industry-wide messages to politicians at Westminster and in Europe, as well as with civil servants and others connected to forming and implementing government policy.

 

Amanda Stuart 

Amanda Stuart, new head of government affairs at the ABPI

 

"With a general election looming, I am looking forward to getting straight down to the business of talking to MPs, parliamentary candidates, researchers and others about the pharmaceutical industry's vital contribution to the health and wealth of the country," Stuart said.

"Whatever the result of the general election, it is crucial that the industry's voice is heard and its messages clearly understood. I relish the task."

Dr Richard Barker, director general of the ABPI, said: "Amanda has a challenging role in challenging times, but I am confident she will play a vital part in making better understood the industry's role in researching, developing and manufacturing increasingly sophisticated medicines to improve people's health."

Stuart, 30, is co-founder of Women in Communications Inc, London, which aims to support women in all areas of communication, including the promotion of female candidates. At Insight, she provided high-level advice to clients in politics and healthcare.

2nd February 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics